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Serum ROBO4 and CLEC14A: preliminary evaluation as diagnostic and progression 
biomarkers in colorectal cancer patients 
Łukasz Pietrzyk1, 2, Kamil Torres1
1. Chair and Department of Didactics and Medical Simulation, Medical University of Lublin, Poland 
2. Department of General, Oncological, and Minimally Invasive Surgery, 1st Military Clinical Hospital 
with the Outpatient Clinic, Lublin, Poland
Introduction. Colorectal cancer (CRC) is an important global burden, and the discovery of 
biomarkers for screening and monitoring is a current challenge. The present study aimed to 
determine the serum concentration of ROBO4 and CLEC14A in CRC patients and assess the 
diagnostic and progression value of these biomarkers in CRC. 
Material and methods. Serum samples were collected from 32 patients with CRC and from 
16 healthy individuals. Blood serum of CRC patients were tested before and after surgery. 
Serum concentration of ROBO4 and CLEC14A were measured using ELISA tests.
Results. The serum concentrations of ROBO4 and CLEC14A were significantly higher in CRC 
patients than non-cancer controls. The sensitivitiy and specificity of ROBO4 and CLEC14A in 
distiguishing cancer patients from controls ranged from 71.9% to 100% and from 84.5% to 
100%, respectively. The serum ROBO4 concentration was associated with the TNM stage, 
depth of invasion, and lymph node and distant metastases. The level of ROBO4 was 
statistically lower 3 months after the surgery, compared to the level noted prior to the 
operation. 
Conclusions. Our preliminary study has provided evidence that ROOB4 and CLEC14A seem to
be suitable biomarkers for clinical diagnostic purposes in colorectal cancer. 
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Introduction
Cancer is an important problem in terms of public health. In developed countries with the 
western diet and lifestyle, cancer causes nearly a quarter of all deaths [1, 2]. Among cancers, 
colorectal cancer (CRC) is the fourth malignancy most commonly detected worldwide and 
represents 9.4% of all cancer incidences in men and 10.1% in women. In 2018, there were 
approx. 1.9 million new CRC cases diagnosed worldwide and approx. 0.9 million deaths from 
colorectal cancer were evidenced [3]. An alarming trend is that CRC patients are shifting 
younger, e.g. the median age in 2001–2002 vs. 2015–2016 was 72 vs. 66 years at diagnosis 
[4]. Since colorectal cancer presents clear symptoms only in advanced stages and there are 
no sensitive and accurate diagnostic methods, the detection of CRC in early stages is 
problematic and difficult [5]. The main therapies applied for CRC are surgical treatment, 
chemotherapy, and radiotherapy. Unfortunately, the survival rate is still poor in distant 
metastatic patients [6]. Even if combined treatments are used, a recurrence occurs in approx.
1/3 of cases, and the median survival after surgery with the best supportive care of 
chemotherapy is up to 24 months [7]. Therefore, the identification of sensitive, reliable, and 
noninvasive biomarkers as screening tests for CRC would be of great advantage, improving 
patient outcomes and declining the mortality rate [8]. In particular:
 diagnostic biomarkers indicating the early stage of the disease, 
 predictive biomarkers that are crucial for the assessment of the risk of cancer 
development, 
 prognostic biomarkers of the risk of cancer progression are required [6]. However, 
regardless of many efforts, there are still no adequate biomarkers for accurate 
prediction and diagnosis of CRC [9].
A critical phase for tumor development and further spread is angiogenesis. Angiogenesis 
supports tumor growth by the influx of essential nutrients and oxygen to the cancer mass 
[11]. It is widely documented that, without new vasculature formation, the maximum size of 
1–2 mm is recognized as the limit for neoplastic expansion [12]. Tumor blood vessels are 
irregular and differ in their morphology (shape and size) and function from normal vessels. 
The endothelial cells of tumor blood vessels exhibit overexpression of molecules named 
tumor endothelial markers (TEMs) [12–14]. Several investigations have indicated that two 
proteins (ROBO4 and CLEC14A) among TEMs are overexpressed on the surface of tumor 
endothelial cells in a wide range of solid tumors (ovary, prostate, breast, liver, bladder, 
kidney, and lung) [15, 16]. 
The ROBO4 (magic roundabout 4) protein has been extensively expressed in 
endothelial cells of various cancer cell lines, including breast and colon cancer, but was not 
identified in such cell lines as fibroblasts and endometrial stromal cells [17]. Moreover, as 
shown by immunohistochemistry analysis, ROBO4 expression was restricted to sites of active 
formation of new blood vessels [18]. It was found that the ROBO4 molecule serves a crucial 
function in tumor neovascularization by initiating vascular endothelial cell migration via 
specific interaction with ligands (i.e. glycoprotein SLITs) [19, 20]. The involvement of the 
ROBO4 protein in pathological angiogenesis indicates that this molecule is a mediator of the 
tumor growth process [21]. Indeed, it has been proved that blocking ROBO activity can cause
inhibition of tumor mass [22]. 
C-type lectin domain family 14 member A (CLEC14A) is considered to be a TEM due to
its overexpression in tumor vasculature, compared to adjacent nontumor blood vessels. High
expression of CLEC14A was observed in head and neck squamous cell carcinoma, breast 
cancers, and clear cell renal cell carcinoma [23,24]. Additionally, studies with CLEC14A (–/–) 
mice proved the promoting role of CLEC14A in tumor growth [24]. 
Although numerous studies have revealed that activation of ROBO4 and CLEC14A 
proteins contributes to angiogenesis and plays a decisive role in tumor growth and 
metastasis, there are limited reports on the expression of these molecules in tissue or blood 
in colorectal cancer patients [19–24]. 
The objective of the present research was to determine the serum concentration of 
ROBO4 and CLEC14A in colorectal cancer patients. Besides, we tried to assess the 
relationship between the levels of the biomarkers in serum and the clinicopathological 
features of CRC patients. The clinical value of ROBO4 and CLEC14A in diagnosis and 
progression of colorectal cancer was also evaluated by comparison with the CEA and CA 19.9 
markers commonly used in clinical practice.
Materials and methods 
Patients, clinical diagnosis, ethics
The study group comprised 48 patients divided into two groups: 32 patients with colorectal 
cancer (CRC group) and 16 healthy individuals (control group). All CRC patients were 
diagnosed and underwent cancer surgery between March 2018 and April 2019. The mean 
age of the CRC patients was 66.14 ± 9.17 years (range: 47–82) After surgery, all resected 
tissues underwent histopathological examination, and the pathologist confirmed CRC in all 
tissue samples. The primary tumour location was the colon in 18 cases (56%) and the rectum 
in 14 cases (44%). The advancement of the tumour stages was assessed by a highly 
specialized pathologist according to the staging system (AJCCS) developed by the American 
Joint Commission on Cancer. Preoperative radiotherapy, chemotherapy, or 
chemoradiotherapy excluded patients from the examination.  
Healthy volunteers (mean age 61 ± 4.59 years, range: 44–79 years) were recruited 
from the patients of the Outpatient Clinic of our hospital during a routine colonoscopy 
screening. The control participants did not take any medical treatment during the study 
period. In addition, the colonoscopy did not reveal any pathological changes. The 
characteristics of the patients enrolled in the study are presented in table I. 
The study was performed according to the Helsinki Declaration 1964 with later 
amendments and approved by the Ethical Committee (decision no. KE-0254/180/2017). In 
accordance with the ethical policy, all participants were adequately informed about the aim 
and methods of the study. As part of the procedure, all patients signed a written consent 
form before the initiation of the research.  
Sample preparation, biomarker assay
Venous blood samples (~10 ml) were collected into commercially available anticoagulant-
treated tubes (EDTA). Blood was taken from the CRC patients at two time points: before the 
surgery (point 0) and postoperatively (point 1), i.e. during the control visit 3 months after the
operation. Blood from healthy individuals was sampled only once. The samples were 
immediately centrifuged at 1000 × g for 10 min at 4°C and the sera were stored at –80°C until
further analysis. The concentrations of ROBO4 and CLEC14a in the serum samples were 
quantified with the use of sandwich ELISA (enzyme-linked immunosorbent assay) according 
to the manufacturer’s instructions (MyBioSource, San Diego, USA). 
The CEA and CA 19.9 serum markers were measured routinely in the CRC patients and
controls using a Cobas 6000 analyzer (Roche Diagnostic, North America). CEA and CA 19.9 in 
the CRC patients were measured at two time points: before and 3 months after the surgery.
Statistical analysis
The data were shown as descriptive statistics (mean ± SD; median with minimum and 
maximum values). Statistical calculations were performed using SPSS software (SPSS 15.0, 
Chicago, IL, USA) and XLSTAT 2018; Data Analysis and Statistical Solution for Microsoft Excel 
(Addinsoft, Paris, France, 2017). Prior to the analyses, the data were tested for normal 
distribution using the Kolmogorov-Smirnov test. As the data indicated non-normal 
distributions, non-parametric tests were applied to compare the serum biomarker levels 
between the studied groups and the serum biomarker levels and clinicopathological 
paramteres. The Mann-Whitney U test was applied to assess the difference between two 
variable groups, while comparisons among multiple groups were performed using the 
Kruskal-Wallis test. Receiver-operating characteristic (ROC) curves were used to determine 
the sensitivity and specificity of serum ROBO4, CLEC14a, CEA, and Ca 19–9. Differences 
between serum biomarker levels from point 0 to point 1 were evaluated with the Wilcoxon 
match-pairs signed ranks test. In all analyses, the differences were considered statistically 
significant when p < 0.05.
Results
Serum levels of ROBO4 and CLEC14A in CRC patients
The serum concentration of ROBO4 and CLEC14A was significantly higher in the CRC patients 
than in the healthy individuals (fig. 1). The mean ROBO4 concentration was approx. 2-fold 
higher in the CRC group, compared to the control (675.50 ± 275.28 pg/ml vs. 339.15 ± 103.27
pg/ml, respectively), while the mean CLEC14A serum level was approx. 4-fold higher in the 
CRC patients than in the non-cancer individuals (50.91 ± 11.28 ng/ml vs. 12.45 ± 5.20 ng/ml, 
respectively). 
Next, the serum levels of ROBO4 and CLEC14A in early-stage (TNM I+II) CRC patients 
were compared with healthy individuals. The mean serum concentrations of both studied 
biomarkers were significantly higher in the TNM stage I+II CRC patients than in the controls 
(fig. 1).  
Evaluation of serum ROBO4 and CLEC14A as potential diagnostic biomarkers for CRC
We used ROC analysis to evaluate the ROBO4 and CLEC14A power in discrimination between 
patients with CRC and healthy controls (tab. II and fig. 2). The ROBO4 protein provided 71.9%
sensitivity, 84.5% specificity, and an AUC of 0.873 (95% CI: 0.778–0.968) in diagnosing CRC. 
The AUC for CLEC14A for discrimination between CRC patients and healthy controls was 1.0; 
the cutoff value of 23.69 ng/ml contributed to 100% sensitivity and specificity. The cutoff 
value for CEA was 6.89 ng/ml and provided sensitivity and specificity of 62.5 and 77.0%, 
respectively (AUC: 0.801; 95 CI: 0.679–0.992). In the case of CA 19.9, the sensitivity and 
specificity were 81.3% and 91.4%, respectively, at the cutoff point of 11.45 ng/ml (AUC: 
0.823; 95 CI: 0.667–0.979).
Relationship between serum levels of ROBO4 and CLEC14A and clinicopathological features
in CRC patients
Table III shows the correlation between serum ROBO4 and CLEC14A levels and 
clinicopathological characteristics in CRC patients. The serum ROBO4 concentration was 
associated with the TNM stage (p < 0.001), depth of invasion (T stage; p < 0.001), and lymph 
node (N stage; p = 0.015), distant metastases (M stage; p = 0.041) and the presence of the 
lymphovascular invasion (p = 0.034). No significant relationship was observed between the 
CLEC14A concentration in the serum and the clinopathological features (tumor site, lymph 
node and distant metastases - N and M stages; in all cases p > 0.05). However, the increased 
CLEC14A levels were associated with the tumor size (p = 0.015), TNM stage (p = 0.001), and 
depth of invasion (T stage; p = 0.002). 
Postoperative changes in serum ROBO4, CLEC14A, CEA, and CA 19.9 concentrations in CRC 
patients
Changes of the serum level of ROBO4, CLEC14A, CEA, and CA 19.9 proteins in the 
postoperative period were assessed (fig. 3). The serum level of ROBO4 and CEA was 
statistically lower at point 1 (3 months after the surgery) compared to the level noted at 
point 0 – prior to the operation (point 0 vs. point 1; ROBO4: 675.50 ± 275.28 vs. 419.21 ± 
166.98 pg/ml, CEA: 12.07 ± 8.25 vs. 7.22 ± 4.70 ng/ml). The serum concentrations of 
CLEC14A and CA 19.9 decreased in the postoperative time period, compared to the 
preoperative level; however, the declines were not statistically significant. 
Discussion
In the recent years, there has been increasing interest in identification of CRC with the use of 
noninvasive biomarkers [8]. The expression of ROBO4 and CLEC14A proteins in tumor 
neovasculature makes these molecules a potential target for use as a diagnostic and 
prognostic indicators of cancer, including CRC [17, 23, 24]. 
To the best of our knowladge, the present study investigated the serum level of 
ROBO4 and CLEC14A in colorectal cancer (CRC) patients for the first time. We found that the 
mean ROBO4 and CLEC14A concentrations in the serum of CRC patients were  significantly 
higher than in the non-cancer controls. Previous literature reports based on 
immunohistochemical methods evidenced specific endothelial expression of ROBO4 and 
CLEC14A in various cell lines, i.e. in MCF-7 breast carcinoma and SY-SH-5Y-neuroblastoma 
cells [15, 17, 19]. Up-regulation of these biomarkers was also proved in human tissues, i.e. in 
vessels of colorectal liver metastases, bladder and breast carcinoma, and liver and kidney 
cancer [15, 19, 26]. Moreover, the expression of ROBO4 and CLEC14A proteins was dominant
at sites of active angiogenesis and in regions exposed to hypoxia [19, 27, 28]. In CRC, up-
regulation of ROBO4 mRNA was detected in more than 70% of carcinoma tissues and this 
protein was exclusively present in the endothelium of cancer vessels [29].    
In our study, the ROBO4 and CLEC14A serum levels increased already in early-stage 
CRC, in comparison to the control samples. Moreover, we found that ROBO4 and CLEC14 had
high power to discriminate between CRC patients and cancer-free individuals. Interestingly, 
the diagnostic sensitivity and specificity of serum CLEC14 reached 100% at the level of 23.98 
ng/ml, which is higher than values noted for CEA (sensitivity: 62.5% and specificity: 77.0%) 
and CA 19.9 (sensitivity: 81.3% and specificity: 91.4%), i.e. biomarkers that are currently 
commonly used in clinical practice. The high predictive ability of CLEC14A was previously 
described by Robinson et al., who performed ROC curve analysis of CLEC14A staining scores 
in various tumor tissues and evidenced their high sensitivity (75%) and specificity (85%) in 
distinguishing between cancer and non-cancer tissue status [30]. The results of our study, 
together with literature data evidencing that ROBO4 and CLEC14A molecules dominate in 
tumor endothelial cells, suggest that these biomolecules have diagnostic potential in cancers,
presumably including CRC [15, 17, 19, 30, 31].  
Further, we analyzed the association between the ROBO4 and CLEC14A serum 
concentrations and clinicopathological features of the CRC patients. In our study, the 
increased ROBO4 levels were related to the depth of tumor invasion as well as lymph node 
and distant metastases. In contrast, the high concentration of CLEC14A was not associated 
with the presence of lymph node and distant metastases. There is scarce information on the 
association between ROBO4 or CLEC14A expression and cancer advancement and prognosis. 
In prostate cancer, a higher histological tumor (Gleason) score was related to overexpression 
of ROBO4 [32]. In acute myeloid leukemia patients, overexpresion of ROBO4 was a poor 
prognostic factor and was corelated with shorter disease-free survival and overall survival 
[33]. Contrasting results were reported by Zhao et al., who evidenced that endothelial 
overexpression of ROBO4 suppressed breast cancer angiogenesis and reduced the speed of 
tumor growth [34]. Simmilary, in non-small lung cancer, high ROBO4 tissue expression was 
related to good prognosis and was connected with normalization of endothelial cells and 
reduction of cancer spread [16]. Considering CLEC14A, recent reports indicate that elevated 
levels of this molecule can inhibit carcinogenesis and progression of lung adenocarcinoma 
[35]. The expression of ROBO4 or CLEC14A molecules in various cancers tissues (up- or 
down-regulation) suggests that these proteins may act as important modulators of 
tumorgenesis and tumor progression. Indeed, ROBO4 and CLEC14A are known as angiogenic 
factors with an essential role in tumor growth. It was revealed that blocking anti-
ROBO4/CLEC14 antibodies induced reduction of the formation of new vessels and led to 
inhibition of cancer mass [25, 31]. Currently, the pro-angiogenic properties of CLEC14A and 
its involvement in tumor growth are well documented [24, 25]. For example, the CLEC14A 
protein promotes filopodia formation and activates cell migration, which is detrimental for 
tumor cell proliferation [15]. Furthermore, the inhibition of the interaction between CLEC14A
and multimerin 2 (MMRN2) by a blocking antibody reduces tumor vessel sprouting and 
hinders the growth of the tumor mass [25]. 
As a novel observation, we found that the ROBO4 serum concentrations decreased 
significantly within 3 months after the surgical removal of CRC. In the case of CLEC14A, we 
documented a tendency of the serum concentration to decline after the operation. 
Therefore, we hypothesized that the level of circulating forms of ROBO4 and CLEC14A is 
associated with the tumor mass. However, we did not find any literatre data to support this 
hypothesis. We can only speculate that resection of solid tumor mass and removal of existing
new vessels that are known to express ROBO4 and CLEC14A proteins result in a decline in the
concentrations of these biomarkers in blood. Prevoiusly, Krishna et al. observed reduction of 
tumor microvessel CLEC14A expresion after preoperative chemotherapy administered to 
patients with epithelial ovarian cancer [36]. It is accepted that chemotherapy performed 
prior to surgical cancer excision contributes to reduction of tumor mass, down staging, and a 
decrease in the expression of cancer-specific molecules, including tumor endothelial markers
[37, 38].
Conclusions
n this preliminary study, higher serum levels of ROBO4 and CLEC14A were observed in the 
CRC patients. Especially, the relationships between ROBO4 and CLEC14A serum levels and 
TNM stages were assesed and a signinficant post-operative decrease in the serum levels of 
these biomarkers was demonstrated.  
Therefore, ROOB4 and CLEC14A seem to be suitable biomarkers for clinical diagnostic 
purposes. Nevertheless, due to the preliminary character of our findings, the results have to 
be taken with caution. In the future, more extensive and prospective studies with a larger 
CRC patient population seem to be required to validate our results. 
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Table I. Characteristics of the colorectal cancer (CRC) patient group  








<5.0 cm  16
≥5.0 cm 16
TNM stage
I + II 18
III + IV 14




lymph node metastases (N-stage)
N0 24







Abbreviations: TNM: (T) tumor; N (nodes), M (metastases)







(%) 95% CI AUC
ROBO4 498.76 71.9 84.5 0.778–0.968 0.873
CLEC14A 23.69 100.0 100.0 1.0–1.0 1.0
CEA 6.89 62.5 77.0 0.679–0.992 0.801
CA 19.9 11.45 81.3 91.4 0.667–0.979 0.823
Abbreviations: ROBO4: roundabout4; CLEC14A: C-type lectin family 14 member A CEA: 
carcinoembryonic antigen, CA 19.9: carbohydrate antigen, CI: confidence interval; AUC: area 
under the curve
Table III. Serum concentration of ROBO4 and CLEC14A in relation to the clinicopathological 
features of CRC patients 














Mann-Whitney U test 0.613 0.464
tumor size
<5.0 cm 
n = 16 
























Mann-Whitney U test <0.001 0.001









































































Mann-Whitney U test 0.044 0.195
Abbreviations: ROBO4: roundabout4; CLEC14A: C-type lectin family 14 member A; TNM: (T) 
tumor; N (nodes), M (metastases); SD: standard deviation; min: minimum; max: maximum; 
significant p-values are indicated in bold
Figure 1. Serum ROBO4 and CLEC14 concentrations in CRC patients and healthy controls
Figure 2. Receiver-Operating Curve (ROC) for ROBO4, CLEC14A, CEA, and Ca19-9
Figure 3. Postoperative changes of serum ROBO4, CLEC14, CEA, and CA 19.9 concentrations 
in CRC patients
